Bardoxolone

Description

Bardoxolone RTA 401; CDDO is an orally active activator of nuclear regulatory factor NRf-2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 ?M in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 ?M by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome SIRS , and cerebral ischemia-reperfusion injury.